Study to Investigate the Chemotherapy-Induced Peripheral Neuropathy (CIPN) Onset-Suppressing Effect and Safety of ONO-2910 in Patients With Breast Cancer Receiving Weekly Paclitaxel

PHASE2CompletedINTERVENTIONAL
Enrollment

210

Participants

Timeline

Start Date

August 31, 2023

Primary Completion Date

September 19, 2024

Study Completion Date

September 19, 2024

Conditions
CIPN - Chemotherapy-Induced Peripheral Neuropathy
Interventions
DRUG

ONO-2910

ONO-2910 Tablet will be orally administered once daily.

DRUG

Placebo

Placebo Tablet will be orally administered once daily.

Trial Locations (30)

Unknown

Fujita Health University Hospital, Aichi

Nagoya City University Hospital, Aichi

Nagoya University Hospital, Aichi

Funabashi Municipal Medical Center, Chiba

Medical Corporation Tesshokai Kameda Medical Center, Chiba

National Cancer Center Hospital East, Chiba

Kitakyushu City Hospital Organization Kitakyushu Municipal Medical Center, Fukuoka

Gunma Prefectural Cancer Center, Gunma

University of Tsukuba Hospital, Ibaraki

Social Medical Corporation Hakuaikai Sagara Hospital, Kagoshima

Nippon Medical School Musashikosugi Hospital, Kanagawa

Tokai University Hospital, Kanagawa

Kumamoto Shinto General Hospital, Kumamoto

Kumamoto University Hospital, Kumamoto

Okayama University Hospital, Okayama

Nahanishi Clinic, Okinawa

Osaka Breast Clinic, Osaka

Osaka Prefectural Hospital Organization Osaka International Cancer Institute, Osaka

Osaka Rosai Hospital, Osaka

Osaka University Hospital, Osaka

Yodogawa Christian Hospital, Osaka

Japanese Saitama Red Cross Hospital, Saitama

Saitama Medical University International Medical Center, Saitama

Shizuoka General Hospital, Shizuoka

Center Hospital of the National Center for Global Health and Medicine, Tokyo

National Cancer Center Hospital, Tokyo

Nippon Medical School Hospital, Tokyo

St. Luke's International Hospital, Tokyo

Tokyo Metropolitan Komagome Hospital, Tokyo

Toranomon Hospital, Tokyo

Sponsors
All Listed Sponsors
lead

Ono Pharmaceutical Co. Ltd

INDUSTRY

NCT06538272 - Study to Investigate the Chemotherapy-Induced Peripheral Neuropathy (CIPN) Onset-Suppressing Effect and Safety of ONO-2910 in Patients With Breast Cancer Receiving Weekly Paclitaxel | Biotech Hunter | Biotech Hunter